Physician profile
Michael J Mahon
NPI 1013904549
$6,176.25
in general payments reported to CMS, 2019-2025
32 companies · $743 in 2025
The $743 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $685 · 2021: $1,046 · 2022: $1,109 · 2023: $1,131 · 2024: $879 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,752.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $937.89 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $840.02 | 2019-2025 | |
| Abbvie INC. | $652.25 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $518.25 | 2020-2025 | Dupixent, Libtayo |
| Amgen INC. | $482.02 | 2021-2025 | Otezla, Enbrel |
| Leo Pharma INC. | $446.23 | 2020-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $362.53 | 2019-2024 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $275.78 | 2019-2025 | |
| Lilly USA, LLC | $263.87 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $220.68 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $172.19 | 2021-2024 | Sotyktu |
| Pfizer INC. | $139.46 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.60 | 2023-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.54 | 2019-2021 | |
| Incyte Corporation | $102.22 | 2022-2024 | Opzelura |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $75.33 | 2019-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $72.05 | 2023 | Vtama |
| Almirall LLC | $64.70 | 2019-2024 | Seysara |
| Genentech USA, INC. | $47.04 | 2019-2024 | Xolair |
| Dermira, INC. | $41.80 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $33.14 | 2024-2025 | Zoryve |
| Organon LLC | $32.85 | 2025 | |
| Fresenius Kabi USA, LLC | $24.20 | 2023 | |
| Verrica Pharmaceuticals INC. | $19.50 | 2024 | Ycanth |
| Botanix Sb INC | $19.32 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $18.24 | 2020 | |
| Aclaris Therapeutics, INC. | $16.41 | 2019 | |
| Strata Skin Sciences, INC. | $16.28 | 2024 | Xtrac |
| Merck Sharp & Dohme LLC | $14.50 | 2019 | |
| Vyne Pharmaceuticals INC. | $14.23 | 2020 | |
| Biofrontera INC. | $11.23 | 2020 | |
| Melinta Therapeutics, LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.